🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease

Recruitingn/aAges any - anyAllXiang Gao
NCT06780683 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Inflammatory Bowel Disease (IBD), which encompasses ulcerative Colitis (UC) and Crohn's Disease (CD), has seen significant improvements in patient outcomes with biologic treatments. However, nearly half of the patients are either primary or secondary non-responders to the existing biologics. Upadacitinib is the only oral small molecule targeted drug approved for IBD in China. There is a paucity of research on the efficacy and safety of upadacitinib in treating Chinese patients with UC and CD, and a lack of study data on the Chinese IBD population. This study aims to conduct a multicenter, single-arm, prospective, observational real-world study to analyze the efficacy and safety of upadacitinib in the treatment of Chinese patients with IBD, providing a basis for clinical decision-making.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Inclusion criteria were patients of any gender, diagnosed with ulcerative colitis or Crohn's disease according to current guidelines, requiring initial upadacitinib treatment as judged by the treating physician, and providing signed informed consent. Exclusion Criteria: * Exclusion criteria included current or planned participation in any other clinical study, contraindications to upadacitinib treatment as per the drug's instructions, and patients deemed unsuitable for the study by the researchers.
💊

What it tests

  • Upadacitinib
📍

Where

6 sites
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine
Guangzhou, China
Sixth Affiliated Hospital, Sun Yat-sen University
Guangzhou, China
Meizhou People's Hospital
Meizhou, China
The Eighth Affiliated Hospital, Sun Yat-Sen University
Shenzhen, China
Liuzhou People's Hospital
Liuzhou, China
Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine
Nanning, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy